Follicular extension of atypical keratinocytes predicts the resistance of actinic keratosis to topical imiquimod treatment: A single-center retrospective analysis.
actinic keratosis
clinical classification
follicular extension
imiquimod
pathological classification
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
17
03
2021
received:
14
02
2021
accepted:
02
04
2021
pubmed:
26
4
2021
medline:
4
8
2021
entrez:
25
4
2021
Statut:
ppublish
Résumé
Topical imiquimod therapy has been widely used for actinic keratosis (AK). However, some cases are refractory to treatment. Therefore, an indicator that can predict its efficacy is desired. Herein, we retrospectively analyzed 52 AK lesions treated with imiquimod to investigate the characteristics of refractory lesions. Imiquimod was applied in a cycle of three times weekly for 4 weeks, followed by a 4-week break. This treatment cycle was repeated up to three times and treatment responses were evaluated. As a result, a complete response (CR) was observed in 78.8% (41/52) of lesions. Next, treatment response of lesions was correlated with clinicopathological characteristics including clinical morphology and thickness, pathological morphology and thickness, and presence of follicular extension (FE). Of these, lesions with FE were significantly less responsive to imiquimod treatment; while 92.6% of AK lesions without FE achieved a CR, only 64.0% of AK lesions with FE achieved a CR (p = 0.029). Logistic regression analysis revealed that FE was the sole significant predictor of its efficacy (p = 0.019). These results suggest that preliminary histological evaluation of FE may be useful to predict the efficacy of imiquimod for AK.
Identifiants
pubmed: 33896047
doi: 10.1111/1346-8138.15914
doi:
Substances chimiques
Aminoquinolines
0
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1262-1267Informations de copyright
© 2021 Japanese Dermatological Association.
Références
Hashim PW, Chen T, Rigel D, Bhatia N, Kircik LH. Actinic Keratosis: current therapies and insights into new treatments. J Drugs Dermatol. 2019;18:s161-s166.
Yu A, Tanizaki H, Kokunai Y, Kaneda K, Sugimoto A, Otsuka T, et al. Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment. J Dermatol. 2018;45:496-500.
Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an overview. Int J Dermatol. 2016;55:831-44.
Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126:1251-5.
Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et al. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol. 2015;29:2069-79.
Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR, McHenry PM, et al. British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176:20-43.
Fernández-Figueras MT, Saenz-Sardà X, Vargas P, Thompson CT, Carrato C, Puig L, et al. The depth of follicular extension in actinic keratosis correlates with the depth of invasion in squamous cell carcinoma: implication for clinical treatment. J Eur Acad Dermatol Venereol. 2018;32:1657-61.
Olsen EA, Lisa Abernethy M, Kulp-Shorten C, Callen JP, Glazer SD, Huntley A, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24:738-43.
Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl 3):8-12.
Filosa A, Filosa G. Actinic keratosis and squamous cell carcinoma: clinical and pathological features. G Ital Dermatol Venereol. 2015;150:379-84.
Sotiropoulou PA, Candi A, Mascré G, De Clercq S, Youssef KK, Lapouge G, et al. Bcl-2 and accelerated DNA repair mediates resistance of hair follicle bulge stem cells to DNA-damage-induced cell death. Nat Cell Biol. 2010;12:572-82.